Subsidiaries

We have developed a unique corporate structure to develop our broad pipeline of oncology drug candidates. This corporate structure involves the formation of joint venture partnerships for select products in various territories to optimize our development efforts and corporate funding.

Our subsidiaries have independent management and substantially independent funding sources, which allows each of our companies to focus on the development of their respective product candidates.

Currently, we have two majority-owned subsidiaries:

  • Incuron, LLC, formed in 2010 to develop product candidates CBL0102 and CBL0137 for oncology indications.
  • Panacela Labs, Inc., formed in 2011 to develop new preclinical product candidates, primarily focused in oncology.
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue